1. Scrip
  2. >>ESG
  3. >>Diversity & Inclusion

For Novavax, Building Trust Was Key To Improving Diversity

Company Took Lead In Native American Vaccine Study Enrollment

 
• By Alaric DeArment

Novavax’s Lisa Dunkle talked to Scrip about the time and effort that went into building trust among Native American communities to encourage participation in its COVID-19 vaccine study.

COVID-19 SARS,Coronaviridae , SARS-CoV, SARSCoV, virus 2020 , MERS-CoV ,chinese virus 2019-nCoV
Novavax relied on building trust to increase diversity in its COVID-19 vaccine trial • Source: Shutterstock

While drug makers are trying to improve the ethnic and racial mix of clinical trial populations, one of the biggest barriers is trust – especially among communities that continue to feel the legacy of mistreatment by the medical system. As Novavax, Inc. worked to improve the diversity of the Phase III PREVENT-19 trial of its COVID-19 vaccine NVX-CoV2373, focusing on trust was one of the ways it successfully bolstered enrollment by Native American participants.

Citeline Award Nominee

Scrip is interviewing the companies shortlisted for the inaugural champion of diversity and inclusion in clinical research award, to highlight some of the best practices in this urgent area. Watch for additional interviews to come, and follow the Citeline Awards, to be held 7 April 2022, for more information.

The company enrolled more than 30,000 adults and adolescents into the PREVENT-19 study, which showed 90.4% overall efficacy and 100%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diversity & Inclusion

Decentralized Trials Enroll Larger, More Diverse Patient Populations

 
• By Alaric DeArment

A new study by Tufts CSDD performed a deep dive into use of decentralized clinical trial techniques, but one of the study’s authors said DCTs have been dialed back.

Pharma Women’s Workforce In India: Weak Start, Promotions, C-Suite Drop Off

 
• By Anju Ghangurde

McKinsey senior partner Vivek Pandit talks to Scrip about some of the intricacies underlying the key findings of a study on pharma’s workforce gender gap in India. Women’s representation starts low at entry level, peaks at senior manager positions and falls off again for C-suite roles, this found.

Parexel Leaders On Trial Diversity, AI And What’s Holding Sponsors Back In India

 
• By Anju Ghangurde

Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 
• By Eleanor Malone

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

More from ESG

Podcast: Amid Talk Of KKR Stake Sale, JB CEO Stresses Business As Usual

 
• By Vibha Ravi

In an interview with JB CEO Nikhil Chopra, Scrip discusses talk of a stake sale by private equity fund KKR, gains from acquisitions including select Novartis brands, plans to ascend to the top five in cardiology and a ramp up of the CDMO business, which has clients including J&J.

Publisher’s Spotlight: The Winners Of The 2024 Citeline Awards

 
• By Mary Jo Laffler

Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston. 

Why Global Pull Incentives Matter For AMR Drugs

 
• By Lisa Takagi

The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.